MedTrace Logo

Treatment Efficacy for Drug Abuse and AIDS Prevention - 1

NCT00000210 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-01-12

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence.

Conditions

  • Cocaine-Related Disorders
  • Heroin Dependence

Interventions

DRUG

Buprenorphine

Sponsors & Collaborators

  • Mclean Hospital

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Jack Mendelson, M.D. · Mclean Hospital

Study Design

Purpose
TREATMENT

Eligibility

Min Age
26 Years
Max Age
41 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1989-09-30
Primary Completion
1996-02-29
Completion
1996-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000210 on ClinicalTrials.gov